MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Let’s Talk Medtech

Diving into Medtech's M&A in 2021

Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers discusses the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report. Hunzinger also talks about some trends in medtech M&A and the rise of the Special Purpose Acquisition Corporation mergers. Plus, MD+DI’s Omar Ford gives insight on Illumina’s controversial acquisition of Grail.

onephoto-stock.adobe.comIMG_Aug262021at30601PM.jpg

This episode of Let’s Talk Medtech is a double-header. We speak with Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers about the state of medtech M&A and take a dive into the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report.

Then, Omar Ford, MD+DI’s Managing Editor, delves into the controversial Illumina/Grail merger.

 

 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish